Table 3.

Tumor response (confirmed best overall response) and clinical benefit by genetic phenotype (n=48)^*

Response	Germline BRCA1or BRCA2 mutation positive, n=14	Germline BRCA1and BRCA2 wild-type n=26	Unknown mutation status n=8	Total, n=48*
Best overall response, n(%)
Complete response (CR)	1 (7%)	1 (4%)	--	2 (4%)
Partial response (PR)	7 (50%)	7 (27%)	1(12%)	15 (31%)
Stable disease (SD)	5 (36%)	12 (46%)	4 (50%)	21 (44%)
Progressive disease (PD)**	1 (7%)	6 (23%)	3 (38%)	10 (21%)
Clinical benefit (PFS6) rate, n(%)	10 (71%)	8/27* (30%)	2 (25%)	20/49 (41%)

^*excludes one patient who withdrew after C1D1 for insurance reasons (unknown mutation status) and one (from response but not PFS6) who withdrew after 2 cycles to avoid study travel and died within 6 months of enrollment (BRCA 1/2 wild-type).

^**includes as PD 2 patients who withdrew consent due to anxiety about disease (BRCA1 mutation positive, unknown mutation status); 2 patients who withdrew early in C1 for worsening disease (BRCA 1/2 wild type), and 2 patients with dose-limiting toxicities (unknown mutation status)

PFS6 = disease progression >6 months after starting study therapy